Myriad Genetics

MYGN · NASDAQ

$5.54+$1.33 (+31.59%)TodayMarket closed · Oct 20, 7:59 PM ET

Prev close $4.21

About MYGN

Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic tests. The company is headquartered in Salt Lake City, Utah and currently employs 2,700 full-time employees. The firm develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The firm is focused on three key areas where it has specialized products, capabilities, and expertise: Oncology, Women's Health, and Mental Health. In oncology, it offers testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. The company also offers the SneakPeek Early Gender DNA Test, which can reveal a baby's gender as early as six weeks into pregnancy. The Company’s testing products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, Foresight, Prequel, Precis Tumor, Precise Liquid, SneakPeek and GeneSight, among others.

Employees: 2,700
Headquarters: Salt Lake City, Utah
Listed: Oct 6, 1995
Sector: Health Care
Industry: Biotechnology
Website: myriad.com

Leadership

Myriad Genetics executives
Name	Title	Since	Age
S. Louise Phanstiel	—	—	66
Samraat Raha	—	2023	52
Benjamin Wheeler	—	—	42
Mark Verratti	—	—	56
Shereen Solaiman	—	—	52
Margaret Ancona	—	—	55
Kevin Haas	—	—	40
Dale Muzzey	—	—	45
Brian Donnelly	—	—	—
Jennifer Fox	—	—	52
Paul Bisaro	—	—	64
Mark Davis	—	—	62
Heiner Dreismann	—	—	71
Rashmi Kumar	—	—	55
Lee Newcomer	—	—	73
Colleen Reitan	—	—	65
Daniel Skovronsky	—	—	51
Matt Scalo	—	2023	—

Revenue by product and region

Fiscal year ended Dec 31, 2025: $824.50M total revenue

By product

Hereditary Cancer$372.40M45.2%
Prenatal$186.30M22.6%
Mental Health$144.10M17.5%
Tumor Profiling$121.70M14.8%

By region

U.S.$768.00M93.1%
RoW$56.50M6.9%

Suppliers and customers

Price correlation is over one year: 1 means the stocks move together, -1 opposite

Myriad Genetics suppliers and customers
Company	Relationship	Country	Correlation
Illumina ILMN	Supplier and customer	US	0.89
Burning Rock Biotech ADR BNR	Supplier and customer	CN	0.81
Progyny PGNY	Customer	US	0.75
Abbott Laboratories ABT	Supplier and customer	US	0.16
Novartis NOVN.SW	Supplier and customer	CH	0.10
Johnson & Johnson JNJ	Supplier and customer	US	-0.29
Roche Holding ROG.SW	Supplier and customer	CH	-0.34
Bristol-Myers Squibb BMY	Supplier and customer	US	-0.48
Merck & Co MRK	Supplier and customer	US	-0.50
Eli Lilly LLY	Supplier and customer	US	-0.57

Similar companies

Companies in the same industry as Myriad Genetics

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.